A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment

NCT01497041 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

35

Enrollment

NETWORK

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung
Carcinoma, Squamous
Carcinoma, Large Cell

Interventions

DRUG: Docetaxel
DRUG: Oxaliplatin

Sponsor

Korean South West Oncology Group